Premium
Pathologic and gene expression features of metastatic melanomas to the brain
Author(s) -
Hamilton Ronald,
Krauze Michal,
Romkes Marjorie,
Omolo Bernard,
Konstantinopoulos Panagiotis,
Reinhart Todd,
Harasymczuk Malgorzata,
Wang YangYang,
Lin Yan,
Ferrone Soldano,
Whiteside Theresa,
Bortoluzzi Stephanie,
Werley Jonette,
Nukui Tomoko,
FallertJunecko Beth,
Kondziolka Douglas,
Ibrahim Joseph,
Becker Dorothea,
Kirkwood John,
Moschos Stergios
Publication year - 2013
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.28029
Subject(s) - medicine , immunohistochemistry , pathology , immune system , craniotomy , cd8 , melanoma , gene expression profiling , gene expression , cancer research , gene , immunology , biology , surgery , biochemistry
BACKGROUND The prognosis of metastatic melanomas to the brain (MBM) is variable with prolonged survival in a subset. It is unclear whether MBM differ from extracranial metastases (EcM) and primary melanomas (PrM). METHODS To study the biology of MBM, histopathologic analysis of tumor blocks from patients' craniotomy samples and whole‐genome expression profiling (WGEP) with confirmatory immunohistochemistry were performed. RESULTS High mononuclear infiltrate and low intratumoral hemorrhage were associated with prolonged overall survival (OS). Pathway analysis of WGEP data from 29 such craniotomy tumor blocks demonstrated that several immune‐related BioCarta gene sets were associated with prolonged OS. WGEP analysis of MBM in comparison with same‐patient EcM and PrM showed that MBM and EcM were similar, but both differ significantly from PrM. Immunohistochemical analysis revealed that peritumoral CD3 + and CD8 + cells were associated with prolonged OS. CONCLUSIONS MBMs are more similar to EcM compared with PrM. Immune infiltrate is a favorable prognostic factor for MBM. Cancer 2013 ;119:2737–2746. © 2013 American Cancer Society .